Full Breakdown
ASU-Developed Urine Test Shows High Accuracy in Early Autism Screening
5/27/2026, 8:02:49 PM
New Urine-Based Screening Tool Demonstrates 90% Sensitivity and 100% Specificity
Researchers at Arizona State University’s Biodesign Center for Health Through Microbiomes, together with collaborators from Harvard Medical School, Rensselaer Polytechnic Institute, and clinical sites in Tennessee and Texas, have introduced a urine-based screening system that measures 17 microbially-derived metabolites (the “MDM System”). In a pilot cohort of 52 children diagnosed with autism spectrum disorder (ASD) and 47 typically developing peers, the test correctly identified 90 % of the ASD cases and produced no false positives, yielding a specificity of 100 %. The assay assigns a score based on how many metabolites exceed reference ranges; a score of one or more flagged 90 % of the autism group.
Current Diagnostic Delays and Gut-Microbiome Research
Standard ASD diagnosis relies on behavioral observation and often requires specialist evaluation, leading to average assessment ages of 47 months in the United States. Earlier detection is linked to improved developmental outcomes. Over the past decade, more than 40 studies have reported elevated gut-derived metabolites in children with autism, suggesting a gut-brain axis involvement. The present study builds on that literature by providing a quantifiable metabolic fingerprint.
Researchers and Institutions Behind the Test
- Christina Flynn, PhD – First author, recent ASU chemical-engineering graduate, research director of the CLIA-certified Autism Diagnostics Laboratory, and senior scientist at Gut Brain Axis Therapeutics.
- James Adams, President’s Professor – Corresponding author, Biodesign Center researcher, also a parent of an adult child with autism.
- Rosa Krajmalnik-Brown, PhD – Director of the Biodesign Center, co-author, veteran of gut-microbiome research.
- Collaborating institutions – Harvard Medical School, Rensselaer Polytechnic Institute, clinical research centers in Tennessee and Texas.
- Analutos (UK) – Partner laboratory performing quantitative metabolite analysis and offering the test internationally.
Study Sample, Metabolite Findings, Performance Metrics
The multicenter sample included children aged 2–11 from Arizona, Massachusetts, Tennessee, and Texas. All ASD participants had confirmed clinical diagnoses using established rating tools. Metabolites elevated in the ASD group derived from amino-acid pathways (tyrosine, tryptophan, phenylalanine) and from yeast/fungal activity. On average, ASD children exhibited three elevated metabolites, whereas control children showed none; some concentrations were 100–1,000 times higher than the highest control values. A secondary targeted phase reported 78 % accuracy, reflecting limited reference standards for certain compounds.
Potential Impact on Early Intervention and Economic Burden
Autism affects roughly 1 in 31 U.S. children, with lifetime care costs averaging $3.6 million per individual. By providing a non-invasive, rapid risk-assessment tool, the MDM System could shorten the diagnostic waiting period, enable earlier therapeutic enrollment, and potentially reduce associated stigma. For children already diagnosed, serial testing may help monitor biochemical response to interventions.
Official Statements & Responses
Researchers emphasized that the urine assay is intended as a triage tool rather than a definitive diagnosis. Flynn noted that the test can identify high-risk children and guide treatment planning. Adams highlighted the link between microbial metabolites and neurotransmitter pathways, suggesting that lowering metabolite levels may improve clinical outcomes. Krajmalnik-Brown described the MDM test as a concrete operationalization of long-standing gut-microbiome hypotheses. The Autism Diagnostics Laboratory announced plans to expand clinical availability while awaiting larger validation studies.
Criticism & Opposition
Independent experts caution that the moderate sample size limits generalizability. The study’s authors acknowledge the need for replication across larger, ethnically diverse cohorts. Financial disclosures reveal that several authors hold patents related to ASD diagnostics and co-own Analutos, raising potential conflict-of-interest concerns. Critics argue that without independent verification, clinical adoption should be deferred.
Conflicting Reports & Gaps
The primary analysis reports 90 % sensitivity, yet the targeted confirmation phase cites 78 % accuracy, indicating variability in performance depending on reference standards. No longitudinal data are available to assess whether metabolite reductions correlate with symptom improvement. Causality between elevated metabolites and ASD pathogenesis remains unproven.
Verbatim Quotes
- “What we've discovered is that 80 to 90% of children with autism have extremely high levels of one or more microbially derived metabolites,” — Christina Flynn, PhD, first author
- “What’s really striking about the bacteria is that they make metabolites that are basically altered versions of serotonin and dopamine,” — James Adams, President’s Professor
- “We think reducing the levels of these metabolites may help these children lead healthier and happier lives, and we encourage children to be screened sooner to receive earlier interventions,” — James Adams
- “I am excited about the MDM test, which includes important microbial metabolites, previously hypothesized to be linked with autism.” — Rosa Krajmalnik-Brown, PhD, director
- “Using this test will tell you which young children are at high risk for being diagnosed with autism, and guide treatment in those who have already been diagnosed to help them lead their best lives.” — Christina Flynn
- “We hope there is a reduction in stigma and shame associated with the condition,” — Christina Flynn
What’s Next
A replication cohort is currently enrolling participants to verify sensitivity and specificity across broader demographics. Regulatory clearance processes are being pursued for U.S. clinical use in 2026. Ongoing trials will examine whether microbiota-targeted therapies can modulate metabolite levels and improve behavioral outcomes, potentially establishing a biomarker-guided treatment pathway.
